Clinical Trials Logo

Salivary Gland Cancer clinical trials

View clinical trials related to Salivary Gland Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06091878 Not yet recruiting - Clinical trials for Salivary Gland Cancer

Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers

INDAGA-UK
Start date: July 1, 2024
Phase:
Study type: Observational

The INDAGA-UK trial is a retrospective, multi-centre observational study in participants with locally advanced and recurrent salivary gland to investigate t its molecular profiling, and to explore new prognostic and druggable markers. We will analyse samples and data from patients diagnosed with salivary gland cancer from 2013 - 2023. Subject and sample identification will occur over a 12-month period. Samples and data will be analysed over the next 12 months prior to study end.

NCT ID: NCT05898373 Not yet recruiting - Clinical trials for Salivary Gland Cancer

Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC

Start date: June 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

(1) To apply Bayesian statistics to screen for the most effective treatment regimen containing recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent vedicitumomab (Edisil, RC48) for locally advanced or metastatic salivary gland ductal carcinoma expressing HER2 in the near future. (2) To explore biomarkers relevant to the efficacy of recombinant humanized anti-HER2 monoclonal antibody-MMAE-coupled vedicitumomab (Edisil, RC48) in the treatment of HER2-expressing locally advanced or metastatic salivary gland ductal carcinoma.

NCT ID: NCT02401763 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis

Start date: April 2015
Phase: N/A
Study type: Observational

Nasopharyngeal carcinoma (NPC) is the tenth leading cancers in Taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.